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Case Report
A Case of Ocular Benign Lymphoid Hyperplasia Treated 
with Bevacizumab Injection 
Doo Hwan Oh, Yeoun Sook Chun, Jae Chan Kim
Department of Ophthalmology, Chung-Ang University College of Medicine, Seoul, Korea
We report the first case of ocular benign lymphoid hyperplasia (BLH) treated with subconjunctival injection of bev-
acizumab (Avastin). A 27-year-old man presented to our clinic with conjunctival masses and limbal neovascularization. 
An incisional biopsy yielded the diagnosis of BLH. The patient was subsequently given a subconjunctival injection of 
bevacizumab (1.25 mg / 0.1 mL). The patient did not experience recurrence or malignant metaplasia during the 
one-year follow-up period. In patients with conjunctival BLH, subconjunctival injection of bevacizumab can be a use-
ful treatment option in patients unable to undergo a surgical procedure due to limbal neovascularization.
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Ocular adnexal lymphoproliferative lesions are lympho-
histologic masses that can appear in various locations, in-
cluding the conjunctiva, orbit, eyelid, lacrimal duct, and 
lacrimal gland. They can be both primary or secondary and 
encompass a wide disease spectrum ranging from benign 
lymphoid hyperplasia (BLH) to malignant lymphoma. 
Conjunctival lymphoproliferative lesions have the best prog-
nosis among ocular lymphoproliferative lesions; the ma-
jority are diagnosed as BLH. It has been reported that more 
than 90% of such lesions do not go on to develop into sys-
temic lymphoma [1]. There is no definitive recommended 
treatment for conjunctival BLH, but reported treatments in-
clude cryotherapy and the combination of surgical excision 
and oral steroid administration [2,3].
 There have also been 
reports of using local radiotherapy to prevent malignant 
proliferation and systemic invasion [4].
 However, cryotherapy 
or surgical excision carry the risk of cosmetic problems due 
to scar formation. Furthermore, localized radiotherapy, cry-
otherapy, or surgical excision would be difficult to perform 
in lesions with limbal neovascularization. As such, we re-
port the first case of conjunctival BLH treated with bev-
acizumab injection.
Case Report
A 27-year-old man with a two year history of bilateral me-
dial conjunctival masses was referred to our hospital. His 
chief complaint was injection of both eyes. His best corrected 
visual acuity was 20/20 and the intraocular pressures in both 
eyes were within normal limits. Color vision testing, auto-
mated visual fields, fundus examination, and extraocular 
muscle function were normal bilaterally. There were no palpable 
masses or edema in the eyelids and there was no exophthalmos. 
Slit lamp examination revealed a protruding hypervascular 
mass with combined medial limbal neovascularization on 
each medial conjunctival surface. Specifically, examination 
revealed a salmon colored, elevated (2 mm), moderately firm 
patch (6 mm × 5 mm) on the nasal conjunctiva of the right 
eye with neovascularization. A faint, salmon colored, ele-
vated (1 mm) mass (5 mm × 4 mm) on the nasal conjunctiva 
of the left eye, with thinner new vessels than in the right eye, 
was also observed (Fig. 1A and 1B). 
Incisional biopsy was performed on the mass in the right 
eye for definitive diagnosis. Pathological examination revealed 
benign lymphohistiocytic infiltrates (Fig. 2). The lymphoid 
reaction showed T cells (CD3+) and B cells (CD20+) with no 
evidence of atypical malignant cells. The patient sub-
sequently underwent a complete physical exam, including 
serology (thyroid function tests) and radiology (chest radiog-
raphy and abdominal unltrasonography), to rule out systemic 
disease. There were no significant findings.     
Given the combination of BLH with hypervascular masses 
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Fig. 1. (A) Slit lamp photograph of the patient’s right eye on initial presentation. Note the size, salmon color, and ele-
vated appearance of the hypervascular lesion. (B) Slit lamp photograph of the patient’s left eye on initial presentation. 
Note the size, faint salmon color, and mildly protruding mass. (C,D) Slit lamp photograph of both eyes 2 months follow-
ing subconjunctival injection of bevacizumab. The lesions appear to be almost completely resolved with no obvious rem-
nants seen on the sclera or conjunctiva. (E) Slit lamp photograph of the patient’s right eye after biopsy.
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Fig. 2. Haematoxylin and eosin staining. (A) ×40 magnification of the lesion biopsied in Fig. 1A. (B) ×200 magnifica-
tion of the same lesion. Note the abundance of lymphocytes and the predominance of T cells (CD3+) and B cells 
(CD20+), a pattern typical of benign lymphoid hyperplasia.
/ 0.1 mL) (Avastin; Genentech, South San Francisco, CA, USA) 
was injected into both medial subconjunctival spaces. Two 
months after injection, both masses had almost completely 
disappeared and the accompanying neovascularization was 
reduced (Fig. 1D and 1E). The patient did not experience re-
currence or any other complications during the one-year 
follow-up period.DH Oh, et al. Ocular Benign Lymphoma Treated with Bevacizumab
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Discussion
Appropriate treatment for ocular BLH remains controversial. 
Many physicians simply recommend observation. The re-
ported treatments for orbital BLH include surgical excision, 
radiation therapy, systemic corticosteroid treatment, chemo-
therapy, and cryotherapy. Chemotherapy can be used for 
lymphoma in the conjunctiva if it coexists with systemic 
lymphoma. One report found the final remission rate to be 
98% for cryotherapy used to treat lymphoma localized in the 
conjunctiva [5]. Additionally, local excision or oral or topical 
corticosteroids can also be considered as treatment options. 
However, in the present case, localized radiotherapy, cry-
otherapy, or surgical excision would have been inappropriate 
treatment options because the lesion was accompanied by 
limbal neovascularization and surgical excision carries the 
risk of postoperative cosmetic defects. As such, bevacizumab 
injection was administered under the assumption that the 
conjunctival BLH, which is often difficult to treat using ex-
isting treatment methods, could be treated by altering the oc-
ular surface blood vessels and lymphatic vessel formation. 
Bevacizumab is an anti-vascular endothelial growth factor 
(VEGF)-A antibody approved to treat metastatic colorectal 
cancer [6]. Recently, it has been reported that anti-VEGF 
antibody may be effective in treating age-related macular 
degeneration and diabetic retinopathy [7,8]. Bevacizumab 
has recently been studied as a treatment option for neo-
vascularization in ocular surface diseases [9-11]. However, 
it is unclear if bevacizumab inhibits lymphangiogenesis. 
Only a handful of experimental approaches deal with the in-
hibition of lymphangiogenesis (e.g., the use of VEGFR1R2-Trap 
[12] or a blocking anti-VEGFR3-antibody [13]). Recently, 
several studies have reported that VEGF-A not only mediates 
hemangiogenesis, but also lymphangiogenesis [14-16]. 
Given this, bevacizumab has been reported to be an inhibitor 
of angiogenesis and lymphangiogenesis on the ocular surface 
[17]. According to this report, bevacizumab also inhibits the 
proliferation of lymphatic endothelial cells. However, there 
has not yet been a report of conjunctival BLH treated with 
bevacizumab.
In this case, we hypothesized that with the inhibition of 
new blood and lymphatic vessel formation due to bev-
acizumab injection, the influx of polyclonal lymphocytes 
would be blocked and the polyclonal lymphocytes that had 
already accumulated would be drained by the existing lym-
phatic vessels. We subsequently observed a dramatic re-
sponse to the local subconjunctival injection of bevacizumab. 
The bevacizumab near the reactive follicle must have been 
sufficient to suppress the inflow of lymphocytes. In the treat-
ment of BLH, a common lymphoma in the conjunctiva, sub-
conjunctival injection of bevacizumab can be a useful treat-
ment option for patients who cannot tolerate a surgical proce-
dure because of limbal neovascularization.
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